Randomized controlled trial for the management of osteoporosis in inflammatory bowel disease

Randomized controlled trial for the management of osteoporosis in inflammatory bowel disease - The management of osteoporosis in inflammatory bowel disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006915

Enrollment

Registered

2011-12-20

Start date

2011-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease

Interventions

Bisphosphonate (risedoronate) Vitamin K (menatetrenone)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Inflammatory bowel disease patients with osteopenia 2)Inflammatory bowel disease patients who were or are going to be treated with corticosteroids (> 5mg/day) for more than 3 months.

Exclusion criteria

Exclusion criteria: 1) Patients already treated for osteoporosis 2) Patients taking warfarin. 3) Patients with stenosis in the esophagus or gut. 4) Patients allergic to medicine. 5) Patients who cannot stand or sit down for more than 30 min. 6) Pregnancy. 7) Patients with severe nephropathy. 8) Patients who are attending other clinical trials. 9) Patients who are not supposed to be suitable for this study by doctors.

Design outcomes

Primary

Measure	Time frame
Bone mineral density 12 months after the treatment	—

Secondary

Measure	Time frame
Bone mineral density 12 months after the treatment. Bone markers, disease activity, side effects.	—

Countries

Japan

Contacts

Public ContactHideki Iijima

Osaka University Graduate School of Medicine Department of Gastroenterology

hiijima@gh.med.osaka-u.ac.jp06-6879-3621

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026